Rapid assay development


Easy to interpret


Applicable to cell lines and biopsy material


Physiologically relevant conditions


True compound binding

Is Your Compound Actually Therapeutic?

CETSA® (Cellular Thermal Shift Assay)

The patented Cellular Thermal Shift Assay (CETSA®) gives a quantitative measure of target engagement and a true physiologically relevant readout of affinity, adding real value to existing efficacy assays. CETSA provides a measure for target engagement, which will help you make the right decisions faster and improve the quality in your discovery programs.

Latest news


Pelago enters into a new collaboration with AstraZeneca

Join our Webinar

Is Your Compound Actually Therapeutic?


A new publication highlights its unique capabilities

About us

Spun out from the Karolinska Institute in 2013, Pelago Bioscience AB was founded to provide and develop the patented Cellular Thermal Shift Assay (CETSA®) for use in determination and quantification of drug–target interactions. The company delivers in situ target engagement studies to accelerate preclinical and clinical drug discovery and diagnostics development. Using CETSA data and applications, drug discovery R&D companies are able to make better and more informed decisions at earlier stages in their projects. This reduces time and money spent on sub optimal compounds and allows faster development of more efficacious new drugs.

The company moved to purpose built laboratories at its current location in 2016 and continues to expand.

Meet us

Meet a Pelago representative at the next upcoming conference or meeting.

San Diego, USA - April 2- 6, 2018

CHI Drug Discovery Chemistry

Review Article on CETSA®